Vigil Neuroscience to Present at Stifel 2022 CNS Days
Rhea-AI Summary
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on neurodegenerative diseases, announced participation in the Stifel 2022 CNS Days conference. CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will join a fireside chat on March 28, 2022, at 9:45 a.m. ET. This event can be accessed via a live webcast on the Vigil website. The company aims to create precision-based therapies by leveraging microglia, the brain's immune cells, for treating various neurodegenerative conditions.
Positive
- None.
Negative
- None.
News Market Reaction – VIGL
In the trading session that priced this news, VIGL declined 24.37%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 CNS Days virtual conference on Monday, March 28, 2022 at 9:45 a.m. ET.
To access a live webcast and subsequent archived recording of this presentation, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com.
About Vigil Neuroscience
Vigil Neuroscience is a microglia-focused therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families.
